试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-07
A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents
编号:NCT04236453登记状态:提前终止企业 / 申办者:Janssen Pharmaceutica N.V., Belgium
药物 / 成分:Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC、Darunavir、Emtricitabine/Tenofovir Alafenamide、Cobicistat
登记的停止原因(原文):COVID-19 pandemic impacted the BE assessment of the trial. The clinical team decided to terminate the trial in order to start a new pivotal BE trial
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-07
Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects
编号:NCT04322227登记状态:提前终止企业 / 申办者:H. Lundbeck A/S
药物 / 成分:Foliglurax 10 mg (treatment A)、Foliglurax 30 mg (treatment B)、Placebo (treatment C)
登记的停止原因(原文):Study termination due to efficacy results of another study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-02
The Sustained Effects of Ketamine
编号:NCT02708849登记状态:提前终止企业 / 申办者:Yale University
药物 / 成分:Ketamine、Lamotrigine、Placebo
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-02
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
编号:NCT03707457登记状态:提前终止企业 / 申办者:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
药物 / 成分:Nivolumab、Anti-GITR Monoclonal Antibody MK-4166、IDO1 inhibitor INCB024360、Ipilimumab
登记的停止原因(原文):Funding/material support withdrawn
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-02
A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma
编号:NCT03890198登记状态:提前终止企业 / 申办者:First Affiliated Hospital Xi'an Jiaotong University
药物 / 成分:LCAR-C182A cells
登记的停止原因(原文):the Preliminary data, progress of this study and the adjustment of the pipeline and strategy .
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-01
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
编号:NCT02387125登记状态:提前终止企业 / 申办者:Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
药物 / 成分:CMB305、G100、Metronomic CPA
登记的停止原因(原文):This study did not meet the efficacy objective
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-01
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
编号:NCT02943668登记状态:提前终止企业 / 申办者:Fred Hutchinson Cancer Center
药物 / 成分:Deferasirox、Laboratory Biomarker Analysis
登记的停止原因(原文):Terminated due to low accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-01
Cannabidiol - an in Vivo Innovative Drug Delivery Study
编号:NCT03471559登记状态:提前终止企业 / 申办者:Central Institute of Mental Health, Mannheim
药物 / 成分:Cannabidiol
登记的停止原因(原文):Two step study, step two was not feasible based on results from phase one.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-01
Neurofeedback In Treatment Resistant Depression
编号:NCT04078438登记状态:提前终止企业 / 申办者:Yeungnam University Hospital
药物 / 成分:neurofeedback augmentation、treatment as usual、psychotherapy placebo sessions
登记的停止原因(原文):Because of researcher foreign training
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-06-30
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma
编号:NCT00003060登记状态:提前终止企业 / 申办者:Louisiana State University Health Sciences Center Shreveport
药物 / 成分:filgrastim、busulfan、cyclophosphamide、cyclosporine
登记的停止原因(原文):lack of patient accrual
查看官方原始记录 ↗